N/A Completed N=21 Randomized Triple-blind Treatment

Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use

Obstructive Sleep Apnea · Central Sleep Apnea (Diagnosis) · Chronic Opioid Use

Source: ClinicalTrials.gov NCT01462084 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcomePrimary: Apnea Hypopnea Index (AHI) — 2.5; 16.3 events/hour

Summary

Prospective, randomized, blinded, cross-over study assessing the effectiveness of adaptive servo-ventilation (ASV) in treating patients who have obstructive sleep apnea (OSA) complicated by central sleep apnea (CSA) due to the chronic use of opioid medications

Outcome Measures

Outcome	Result	p-value
PRIMARY Apnea Hypopnea Index (AHI)	2.5; 16.3	—
SECONDARY Patient Comfort	76.0; 67.8	—

Eligibility Criteria

Inclusion Criteria

At least 18 years old
Taking opioid medications for at least 6 months. Opioid medications include but are not limited to: oxycodone, fentanyl, methadone, levorphanol, hydromorphone, and morphine
Using bi-level PAP for at least 30 days

Exclusion Criteria

Primary heart or lung disease, for example: chronic obstructive pulmonary disease, pulmonary fibrosis, severe heart failure, uncorrected congenital heart disease, pulmonary hypertension
Primary neurologic disease, for example: neuromuscular disease, previous stroke or cognitive impairment
Narcolepsy
Acute upper respiratory tract infection
Pregnant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01462084). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.